0001237899-20-000016.txt : 20200413
0001237899-20-000016.hdr.sgml : 20200413
20200413192331
ACCESSION NUMBER: 0001237899-20-000016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200409
FILED AS OF DATE: 20200413
DATE AS OF CHANGE: 20200413
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Landry Robert E
CENTRAL INDEX KEY: 0001585160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20789687
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-04-09
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001585160
Landry Robert E
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP Finance CFO
Common Stock
2020-04-09
4
M
0
3500
272.7
A
27873
D
Common Stock
2020-04-09
4
F
0
2672
508.25
D
25201
D
Common Stock
2020-04-13
4
S
0
99
505.6
D
25102
D
Common Stock
2020-04-13
4
S
0
38
506.24
D
25064
D
Common Stock
2020-04-13
4
S
0
30
507.45
D
25034
D
Common Stock
2020-04-13
4
S
0
115
508.54
D
24919
D
Common Stock
2020-04-13
4
S
0
170
509.45
D
24749
D
Common Stock
2020-04-13
4
S
0
143
510.43
D
24606
D
Common Stock
2020-04-13
4
S
0
156
511.59
D
24450
D
Common Stock
2020-04-13
4
S
0
31
512.58
D
24419
D
Common Stock
2020-04-13
4
S
0
46
517.71
D
24373
D
Common Stock
172
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
272.7
2020-04-09
4
M
0
3500
0.0
D
2023-09-09
Common Stock
3500
39000
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 30 shares of Company stock on April 13, 2020 at prices ranging from $507.44 to $507.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 115 shares of Company stock on April 13, 2020 at prices ranging from $508.24 to $508.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 170 shares of Company stock on April 13, 2020 at prices ranging from $509.03 to $509.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 143 shares of Company stock on April 13, 2020 at prices ranging from $510.11 to $510.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 156 shares of Company stock on April 13, 2020 at prices ranging from $511.23 to $511.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 31 shares of Company stock on April 13, 2020 at prices ranging from $512.01 to $512.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.
The stock option award vests in four equal annual installments, commencing one year after the date of grant.
/s/**Robert E. Landry
2020-04-20